|
Characteristics
|
n = 90
|
|---|
|
PD
|
57 (63)
|
|
RECIST
|
51 (89)
|
|
Clinical
|
5 (9)
|
|
Both
|
1 (2)
|
|
Patients with new organ sites at time of RECIST PD
|
23 (44)
|
|
New organ sites at time of RECIST PD
|
|
Brain
|
8 (35)
|
|
Bones
|
1 (4)
|
|
Liver
|
4 (17)
|
|
Soft tissue
|
4 (17)
|
|
Pleural
|
1 (4)
|
|
Local
|
4 (17)
|
|
Adrenal
|
3 (13)
|
|
Management after PD
|
|
Subsequent systemic treatment
|
28 (49)
|
|
Hospice
|
23 (40)
|
|
Died
|
3 (5)
|
|
Subsequent therapies in PD group after nivolumab discontinued
|
|
Cabozantinib
|
6 (21)
|
|
Axitinib
|
14 (50)
|
|
Everolimus
|
1 (4)
|
|
Temsirolimus
|
3 (11)
|
|
Sunitinib
|
2 (7)
|
|
Others*
|
2 (7)
|
- *One patient was enrolled in a clinical trial investigating an experimental drug in combination with Atezolizumab. A second patient was enrolled in a clinical trial and randomized to receive tivozanib
